Class summary at a glance.

Every drug in the Proton Pump Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 10tracked in Part D
CY24 Part D spend: $1.50Bcombined across class
Total Rx claims: 85.9M27.4M unique beneficiaries
Generic mfrs (active): 79across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Omeprazole

Brand: Prilosec · 43.3M Part D claims (CY24) · 13.9M beneficiaries · First FDA approval: 2002-11-04

13 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.029

→

Avg plan cost$0.510

Part D spend $516.8M 18× spread, current vs floor

Class share

34%

of class CY24 spend

View profile →

Pantoprazole

Brand: Protonix · 39.0M Part D claims (CY24) · 12.4M beneficiaries · First FDA approval: 2000-05-01

29 generic mfrs 0 plans require PA

Low NADAC$0.035

→

Avg plan cost$1.47

Part D spend $499.9M 42× spread, current vs floor

Class share

33%

of class CY24 spend

View profile →

Dexlansoprazole

Brand: Dexilant · 1.3M Part D claims (CY24) · 352K beneficiaries · First FDA approval: 2010-04-12

4 generic mfrs 0 plans require PA

Low NADAC$4.21

→

Avg plan cost$5.46

Part D spend $361.2M 1× spread, current vs floor

Class share

24%

of class CY24 spend

View profile →

Lansoprazole

Brand: Prevacid · 1.9M Part D claims (CY24) · 610K beneficiaries · First FDA approval: 1995-05-10

13 generic mfrs 0 plans require PA

Low NADAC$0.108

→

Avg plan cost$1.35

Part D spend $83.6M 13× spread, current vs floor

Class share

of class CY24 spend

View profile →

Rabeprazole

Brand: Aciphex · 447K Part D claims (CY24) · 154K beneficiaries · First FDA approval: 2013-11-08

8 generic mfrs 0 plans require PA

Low NADAC$0.215

→

Avg plan cost$0.215

Part D spend $40.6M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Esomeprazole

Brand: NEXIUM · 183 Part D claims (CY24) · First FDA approval: 2001-03-19

4 generic mfrs 0 plans require PA

Low NADAC$0.139

→

Avg plan cost$1.69

Part D spend $44416 12× spread, current vs floor

Class share

of class CY24 spend

View profile →

Lansoprazole Dr

— Part D claims (CY24) · First FDA approval: 2022-08-08

Brand-only (no generics)

Low NADAC$0.108

→

Avg plan cost$1.28

Part D spend — 12× spread, current vs floor

Class share

of class CY24 spend

View profile →

Omeprazole Sodium Bicarbonate

— Part D claims (CY24) · First FDA approval: 2017-01-30

8 generic mfrs

Low NADAC$0.483

→

Avg plan cost$0.538

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Omeprazole and Sodiium Bicarbonate

— Part D claims (CY24) · First FDA approval: 2024-08-12

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Omeprazole and Sodium Bicarbonate

Brand: Konvomep · — Part D claims (CY24) · First FDA approval: 2004-06-15

Brand-only (no generics) 4 plans require PA

Low NADAC$0.483

→

Avg plan cost$4.85

Part D spend — 10× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.